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ABSTRACT 
Simple, precise and accurate UV-Spectrophotometric simultaneous equation method for estimation of dapagliflozin (DAPA) and saxagliptin 
(SAXA) were developed and validated as per ICH guidelines. This Method involves solving of simultaneous equations based o n measurement of 
absorbance at two wavelengths 222 nm and 276 nm (λmax of SAXA and DAPA) in phosphate buffer pH 6.8. Both the drugs obey the Beer’s law in 
the concentration ranges 5-25µg/ml. % Recovery for both the drugs were in the range of 98.44-99.05% indicating excellent accuracy. The 
methods were precise, with a relative standard deviation of less than 2% for both drugs. The developed methods were validated according to 
ICH guidelines and values of accuracy, precision and other statistical analysis were found to be in good accordance with the prescribed values. 
Thus, method can be used for routine monitoring of drugs in industry for the assay of bulk drugs and commercial formulation (QTERN tablets, 
Astra Zeneca). 
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INTRODUCTION 
Saxagliptin is chemically called as (1S, 3S, 5S)-2-[(2S)-2-
Amino-2-(3 hydroxytricyclo [3.3.1.13, 7] dec-1-yl) acetyl]-2-
azabicyclo [3.1.0] hexane-3-carbonitrile (Figure 1A). It is the 
oral hypoglycemic (antidiabetic) agent, class of dipeptidyl 
peptidase (DPP-4) inhibitor [1]. Saxagliptin was inhibiting 
the activity of dipeptidyl peptidase-4(DPP-4) enzyme by 
increasing the insulin production in response to meal and 
decreasing the gluconeogensis rate in the liver, in blood 
glucose regulation is thought to be through degradation of 
GIP [2] and the degradation of GLP-1 [3]. Saxagliptin was 
used for the treatment of type-2 diabetics in the form of 
mono or combination of with other drugs. Dapagliflozin is 
chemically called as (1S)-1, 5-anhydro-1-C-[4- chloro-3-[(4-
ethoxyphenyl) methyl] phenyl]-D-glucitol (Figure 1B). It is a 
highly selective, sodium-Glucose Co-Transporter 2 (SGLT2). 
Dapagliflozin blocking the activity of the sodium-glucose 
transport proteins, which is regulates for at least 90% of the 
glucose reabsorption in the kidney and obstructs the 
transporter mechanism causes blood glucose to be removed 
through the urine. Dapagliflozin is improved the glyceamic 
control in patients with type 2 Diabetes Mellitus [4]. A 
survey of literature revealed the availability of number of 
analytical methods for the quantitative determination of 
DAPA and SAXA alone or combination with other drugs. The 
reported methods were mainly based on liquid 
chromatographic estimation using UV-VIS, fluorescence, 
electrochemical or mass spectrometry detectors. The 
available methods are based on spectrophotometry, thin 
layer chromatography or high performance liquid 
chromatography [5-23]. However, no UV-
Spectrophotometric simultaneous equation method is 
available for simultaneous determination of the DAPA and 
SAXA in combined pharmaceutical dosage form. In the 
present study, an attempt was made to develop a simple, 
precise and accurate method for the simultaneous 
estimation of these drugs in combined pharmaceutical 
dosage form and validate as per International Conference on 
Harmonization (ICH) guidelines. 
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Figure 1 Chemical structure of (A) Saxagliptin and (B) 
Dapagliflozin 
METERIALS AND METHODS 
Reagents and chemicals 
DAPA and SAXA standard were obtained from scan research 
laboratories, Bhopal as gift sample. QTERN tablets 
Purchased from Local market. Methanol, acetonitrile were 
procured from Rankem, RFCL Limited, New Delhi, India. 
Potassium dihydrogen phosphate AR and NaOH AR grade 
were procured from Merck. Milli Q water was used 
throughout the study. Other chemicals used were of 
analytical grade. 
Instrument 
In UV-spectrophotometric method, Labindia model-3000+ 
series was used, which is a wavelength accuracy ±1 nm, with 
1cm quartz cells. 
Method development 
Standard stock solution (Stock-A) 
Standard stock solutions were prepared by dissolving 
separately 100 mg of each drug in 80ml phosphate buffer pH 
6.8 in 100 ml volumetric flask. The flask was sonicated for 
about 10 min to solubilizing the drug and the volume was 
made up to the mark 100ml with phosphate buffer pH 6.8 to 
get a concentration of 1000 µg/ml (Stock-A) for both drugs. 
Sub Stock Solution (Stock-B) 
Aliquots of 2.5 ml withdrawn with help of pipette from 
standard stock solution A of SAXA and DAPA and transferred 
into 25 ml volumetric flask separately and diluted up to 25 
ml with phosphate buffer pH 6.8 that gave concentration of 
100 µg/ml (Stock-B). 
Determination of λmax 
10 µg/ml standard solutions of both SAXA and DAPA were 
prepared from respective sub-stock solutions. Both the 
solutions were scanned in the wavelength region of 200-400 
nm and the λmax was found to be 222 nm and 276 nm for 
SAXA and DAPA respectively. They were scanned in the 
wavelength range of 200-400 nm and the overlain spectrum 
was obtained (Figure 2-4). 
 
Figure 2 Determination of λmax of SAXA  
 
Figure 3 Determination of λmax of DAPA 
 
Figure 4 overlay spectra of SAXA and DAPA 
 
Preparation of calibration curve 
From the standard stock solution of each drug, appropriate 
aliquots were pipette out into a series of 10 ml volumetric 
flasks. The volume was made up to the mark with phosphate 
buffer pH 6.8 to get a set of solutions having a concentration 
range of 5-25µg/ml for both drugs. Triplicate dilutions of 
each drug solutions were prepared separately. The prepared 
working solutions of SAXA and DAPA were scanned 222 nm 
and 276 nm, respectively. The absorbance’s were recorded 
and were plotted against the concentrations to obtain their 
respective calibration curves.  
Simultaneous equation method (Vierordt’s) 
Working standard solution from the standard stock solution 
prepared in concentration 40μg/ml of SAXA and 2μg/ml of 
DAPA were scanned in the spectrum mode over the range of 
200-400 nm against phosphate buffer pH 6.8 as blank and 
the overlain spectra of the two were recorded. SAXA showed 
an absorbance peak at 222.0 nm, whereas DAPA at 276.0 nm. 
The overlain spectra also showed isoabsorptive points at 
235.0 nm. Due to difference in absorbance maxima and 
having no interference with each other so both drug can be 
simultaneously estimated by simultaneous equation method. 
Simultaneous equation method is based on the absorption of 
drugs (X and Y) at the wavelength maximum of the other. 
Two wavelengths selected for the method are 222.0 nm and 
276.0 nm that are λmax of SAXA and DAPA respectively. The 
absorbances were measured at the selected wavelengths and 
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absorptivities (A1%, 1cm) for both the drugs at both 
wavelengths were determined as mean of five independent 
determinations. Concentrations in the sample were obtained 
by using following equations  
 
Where, A1 and A2 are absorbances of mixture at 222.0 nm and 
276.0 nm respectively, ax1 and ax2 are absorptivities of SAXA 
at λ1 (222.0 i.e. λmax of SAXA) and λ2 (276.0 i.e. λmax of DAPA) 
respectively and ay1 and ay2 are absorptivities of DAPA at λ1 
and λ2 respectively. CDAPA and CSAXA are concentrations of 
SAXA and DAPA respectively. Figure 4 represent the 
overlain spectra of both the drugs and the criteria for 
obtaining  maximum precision [i.e. absorbance ratio 
(A2/A1)/ax2/ax1 and ay2/ay1] by this method were 
calculated and found to be outside the range of 0.1-2.0 
which is satisfied for both the SAXA and DAPA [24]. 
Methods validation  
Validation of the method was carried out in accordance with 
the International Conference on Harmonization Q2B 
guidelines 2005 [25].  
Linearity 
The linearity of analytical method was carried out to check 
its ability to elicit test results that are proportional to the 
concentration of analyte in sample within a given range. 
Different levels of standard solutions were prepared and 
estimate into the UV and the results was recorded. The 
results of linearity are reported in Table 1 and figure 5 & 6.  
Accuracy 
The validity and reliability of proposed methods were 
assessed by recovery studies by using standard addition 
method. The recovery of added standards (80%, 100% and 
120%) was found at three replicate and three 
concentrations level. The value of % means just close to 100, 
SD and % RSD are less than 2 indicate the accuracy of 
method. Result of recovery study shown in Table 2. 
Precision 
Precision was determined by repeatability and Intermediate 
precision (Day to day precision, Analyst-to-Analyst) of drug. 
Repeatability result indicates the precision under the same 
operating condition over short interval time. The 
intermediate precision study is expressed within laboratory 
variation on different days and analyst to analyst variation 
by different analyst. The value of SD and %RSD are less than 
2 indicate the precision of method. Result of precision 
shown in Table 3. 
Detection Limit and Quantitation Limit 
The LOD and LOQ of developed method were calculated 
based on the standard deviation of response and slope of the 
linearity curve Table 4.  
Assay of Tablet Formulation 
Mixed Blends of SAXA and DAPA were weighed and ground 
to a fine powder; amount equal to 10mg of DAPA was taken 
in 10 ml volumetric flask. The present in this amount of 
marketed tablets (QTERN tablet, Astra Zeneca) was 5mg 
SAXA. Then 5ml of phosphate buffer pH 6.8 was added and 
the flask was sonicated for about 10 min to solubilizing 
the drug present in tablet formulation and the volume 
was made up to the mark with Buffer. After sonication 
filtration was done through Whatman filter paper No. 41. 
Filtrate was collected and further diluted with buffer to get 
the final concentrations of both drugs in the working range. 
The absorbance of final dilutions was observed at selected 
wavelengths and the concentrations were obtained from 
simultaneous equation method. The procedure was repeated 
for five times Table 5. 
 
Figure 5: Calibration Curve of SAXA 
 
Figure 6: Calibration Curve of DAPA 
 
RESULTS AND DISCUSSION 
Method development by UV-Spectrophotometer is cost 
effective and time saving as compared to HPLC method of 
analysis [26].  Thus, for estimation of routine sample of 
drugs simple, rapid, sensitive and accurate analytical UV 
methods were utilized which reduces unnecessary tedious 
sample preparations and use of costly materials. To develop 
suitable methods of analysis, various solvents were studied. 
Based on sensitivity of the method and non-toxic behaviour 
phosphate buffer pH 6.8 was selected as a solvent for the 
methods. Overlain spectra (Figure 4) shows that at λmax of 
SAXA (222 nm) interference of DAPA and at λmax of DAPA 
(276nm) interference of SAXA occurs which suggested 
development of simultaneous equation method. The 
optimized methods showed good reproducibility and mean 
recovery with 98.956± 0.114 (SAXA), 99.090±0.141 (DAPA) 
and 98.870±0.951 (SAXA), 99.059±0.358 (DAPA) 
respectively. The standard deviation, coefficient of variance 
and standard error were obtained for SAXA and DAPA were 
satisfactorily low. Result of precision at different levels was 
found to be within acceptable limits (RSD < 2). Thus, the 
method provides a simple, convenient, rapid and accurate 
way to determine SAXA and DAPA simultaneously. 
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CONCLUSION 
A new, simple, sensitive and economical UV 
spectrophotometric method was developed for the 
simultaneous estimation of SAXA and DAPA in their tablet 
formulation. Validation of developed methods was 
performed according to ICH guidelines. The standard 
deviation, % RSD for the methods are low, reflecting a high 
degree of precision of the methods. The results of the 
recovery studies performed show the high degree of 
accuracy of the proposed methods. Vierordt’s method has 
the advantage of being simple, economic, rapid and 
subsequently not required sophisticated technique, 
instrument and costly solvents. Thus, the proposed methods 
can be successfully applied for determination and 
dissolution testing of SAXA and DAPA in commercial 
formulation (Qtern).  
Table 1 Results of Linearity of Saxagliptin and 
Dapagliflozin 
PARAMETER Saxagliptin Dapagliflozin 
Concentration (μg/ml) 5-25 5-25 
Correlation Coefficient 
(r2)* 
0.999 0.999 
Slope (m)* 0.037 0.038 
Intercept (c)* 0.000 -0.002 
*value of three replicate 
Table 2 Results of Recovery Study 
% LEVEL % MEAN±SD* 
 Saxagliptin Dapagliflozin 
80% 98.736±1.076 98.549±1.875 
100% 98.870±0.951 99.059±0.358 
120% 98.449±0.211 99.000±0.465 
* Value of three replicate and five concentrations. 
Table 3 Results of Precision 
PARAMETER 
% MEAN±SD* 
Saxagliptin Dapagliflozin 
Repeatability 99.086±0.084 98.860±0.064 
             Intermediate precision  
Day to day precision 99.071±0.070 99.070±0.107 
Analyst-to-Analyst  98.816±0.107 99.345±0.087 
Reproducibility 98.956± 0.114 99.090±0.141 
* Value of five replicate and five concentrations 
Table 4 LOD and LOQ OF SAXA and DAPA 
Name LOD (g/ml) LOQ (g/ml) 
Saxagliptin 1.23 3.25 
Dapagliflozin 0.95 2.72 
 
 
Table 5 Assay of Tablet Formulation 
 % Conc. Found 
  SAXA  DAPA 
Mean   98.092 93.070 
S.D. 1.708 10.573 
% RSD 1.742 11.360 
*Average of three replicate 
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